15 Apr 2015 08:59
Cathay International Holdings Limited
("Cathay" or the "Company")
Transaction in Own Shares
Hong Kong, 15 April 2015 - Cathay International Holdings Ltd. (LSE: CTI.L), an investment holding company and a leading operator and investor in the growing healthcare sector in the People's Republic of China, today announces that on 14 April 2015 it purchased the following number of its common shares.
Number of common shares purchased: | 60,000 |
Highest price paid per common share (pence): | 22.00 |
Lowest price paid per common share (pence): | 21.00 |
Average price paid per common share (pence): | 21.83 |
All the purchased shares will be held as treasury shares. Following the purchase of these shares, the Company holds 64,644 of its common shares in treasury and has 371,892,361 common shares in issue (excluding treasury shares).
For further enquiries, please contact:
Cathay International Holdings Limited Eric Siu (Finance Director) Patrick Sung (Director and Controller) |
Tel: +852 2828 9289 |
Consilium Strategic Communications Mary-Jane Elliott / Amber Bielecka / Matthew Neal / Lindsey Neville |
Tel: +44 (0)203 709 5708
|
About Cathay
Cathay International Holdings Limited (LSE: CTI.L) is a main market listed investment holding company and a leading operator and investor in the growing healthcare sector in the People's Republic of China ("PRC"). The Company and its subsidiaries (collectively the "Group") aim to leverage on growth opportunities in the strong and growing domestic demand for high quality healthcare products in China and build its portfolio companies into market sector leaders with competitive edge. Cathay has already demonstrated a strong track record of identifying high-growth potential investment opportunities in this area including: Lansen, China's leading specialty pharmaceutical company focused on rheumatology and dermatology; Haizi, a company engaged in the manufacture, marketing and sales of inositol and its by-product, di-calcium phosphate; Yangling, a company engaged in production and sales of plant extracts for use as key active ingredients in healthcare products; and Botai, a company engaged in collagen products.
The Group employs approximately 2,000 people across the PRC, including over 30 specialist corporate and business development staff based at the holding company's offices in Hong Kong and Shenzhen. Cathay also has a hotel investment.
For more information please visit the Company's website: www.cathay-intl.com.hk
CTI.L (CTI)